DNX BIOTHERAPEUTICS INC has a total of 14 patent applications. Its first patent ever was published in 1993. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets biotechnology, agriculture and pharmaceuticals are BRESATEC LTD, STERRENBELD BIOTECHNOLOGIE NORTH AMERICA INC and IMMUNOVA.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | Finland | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Japan | 1 | |
#8 | Norway | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Agriculture | |
#3 | Pharmaceuticals | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Animal care | |
#2 | Peptides | |
#3 | Microorganisms | |
#4 | Medical preparations | |
#5 | Therapeutic chemical compounds | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Kumar Ramesh | 7 |
#2 | Sharma Ajay | 7 |
#3 | Logan John S | 7 |
#4 | Byrne Guerard W | 5 |
#5 | Logan John Steele | 4 |
#6 | Kooyman David Lee | 4 |
#7 | Bennett C Frank | 1 |
#8 | Khoury-Christianson Anastasia | 1 |
#9 | Kooyman David L | 1 |
#10 | Grass David S | 1 |
Publication | Filing date | Title |
---|---|---|
US5625125A | Phospholipase A2 expressing transgenic animals | |
US5821351A | Production of hemoglobin having a delta-like globin | |
US5627268A | Hemoglobin comprising globin fusion proteins | |
CA2144767A1 | Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes |